Published in Br J Clin Pharmacol on February 01, 1994
The psychomotor and cognitive effects of litoxetine in young and middle aged volunteers. Br J Clin Pharmacol (1995) 0.76
Psychomotor function and psychoactive drugs. Br J Clin Pharmacol (1980) 3.57
Topographic brain mapping of EEG in neuropsychopharmacology--Part II. Clinical applications (pharmaco EEG imaging). Methods Find Exp Clin Pharmacol (1987) 0.98
Psychopharmacological effects of sertraline in normal, healthy volunteers. Eur J Clin Pharmacol (1988) 0.92
The psychopharmacological effects of repeated doses of fluvoxamine, mianserin and placebo in healthy human subjects. Eur J Clin Pharmacol (1986) 0.91
The effects of citalopram in single and repeated doses and with alcohol on physiological and psychological measures in healthy subjects. Eur J Clin Pharmacol (1986) 0.90
Litoxetine: a selective 5-HT uptake inhibitor with concomitant 5-HT3 receptor antagonist and antiemetic properties. Eur J Pharmacol (1993) 0.89
Activity of litoxetine and other serotonin uptake inhibitors in the tail suspension test in mice. Pharmacol Biochem Behav (1992) 0.89
On central effects of serotonin re-uptake inhibitors: quantitative EEG and psychometric studies with sertraline and zimelidine. J Neural Transm (1986) 0.88
Psychotropic drug profiles: comparisons by topographic maps of absolute power. Neuropsychobiology (1987) 0.85
Acute effects of sertraline, amitriptyline, and placebo on the psychomotor performance of healthy subjects over 50 years of age. J Clin Psychiatry (1988) 0.85
The effect of paroxetine on the quantitative EEG. Acta Psychiatr Scand Suppl (1989) 0.82
CNS effects of citalopram, a new serotonin inhibitor antidepressant (a quantitative pharmaco-electroencephalography study). Prog Neuropsychopharmacol Biol Psychiatry (1984) 0.81
Classification and determination of cerebral bioavailability of fluoxetine: pharmacokinetic, pharmaco-EEG, and psychometric analyses. J Clin Psychiatry (1985) 0.81
Double-blind comparisons of a selective serotonin reuptake inhibitor, zimelidine, and placebo on quantified EEG parameters and psychological variables. Acta Psychiatr Scand Suppl (1981) 0.80
Drug profiling by computed electroencephalography and brain maps, with special consideration of sertraline and its psychometric effects. J Clin Psychiatry (1988) 0.79
Computer EEG drug data base in psychopharmacology and in drug development. Psychopharmacol Bull (1982) 0.79
Anorectic activities of serotonin uptake inhibitors: correlation with their potencies at inhibiting serotonin uptake in vivo and 3H-mazindol binding in vitro. Life Sci (1988) 0.78
EEG and psychopharmacology. Electroencephalogr Clin Neurophysiol Suppl (1978) 0.78
Studies of the absorption and removal of propranolol in hypertensive patients during therapy. Circulation (1975) 1.92
N-desmethyldiazepam and amylobarbitone sodium as hypnotics in anxious patients. Plasma levels, clinical efficacy and residual effects. Psychopharmacologia (1975) 1.54
Delayed absorption of phenylbutazone caused by desmethylimipramine in humans. Eur J Pharmacol (1970) 1.47
Hypotensive and renin-suppressing activities of propranolol in hypertensive patients. Clin Sci Mol Med Suppl (1975) 1.46
Zolpidem side-effects. Lancet (1993) 1.37
A sensitive gas chromatographic method for the determination of propranolol in human plasma. J Chromatogr (1973) 1.34
Population pharmacokinetic analysis of mizolastine and validation from sparse data on patients using the nonparametric maximum likelihood method. J Pharmacokinet Biopharm (1998) 1.33
Sensitive gas chromatographic method for the determination in blood and urine of SL 75212 [4-(2-cyclopropylmethoxyethyl)-1-phenoxy-3-isopropylaminopropan-2-ol], a new beta 1 adrenoceptor blocking agent. J Chromatogr (1979) 1.30
Gas chromatographic method for the determination of nomifensine in human plasma. J Chromatogr (1976) 1.29
Clinical pharmacokinetics in newborns and infants. Age-related differences and therapeutic implications. Clin Pharmacokinet (1981) 1.29
Large changes in Pluto's atmosphere as revealed by recent stellar occultations. Nature (2003) 1.28
Duration between onset and time of obtaining initial treatment among people with anxiety and mood disorders: an international survey of members of mental health patient advocate groups. Psychol Med (2000) 1.26
Pharmacokinetics and effects of propranolol in terminal uraemic patients and in patients undergoing regular dialysis treatment. Clin Pharmacokinet (1976) 1.25
Comparison of the pharmacokinetic profiles of three low molecular mass heparins--dalteparin, enoxaparin and nadroparin--administered subcutaneously in healthy volunteers (doses for prevention of thromboembolism). Thromb Haemost (1995) 1.25
Effectiveness and pharmacokinetics of indomethacin in premature newborns with patent ductus arteriosus. Eur J Clin Pharmacol (1980) 1.23
Further observations on the interactions between phenobarbital and diphenylhydantoin during chronic treatment in the rat. Biochem Pharmacol (1972) 1.18
Interaction between phenobarbital and diphenylhydantoin in animals and in epileptic patients. Ann N Y Acad Sci (1971) 1.16
Metabolism and Pharmacolinetics of Carbamazepine. Drug Metab Rev (1975) 1.15
Diazepam elimination in premature and full term infants, and children. J Perinat Med (1973) 1.15
Pharmacokinetics of nomifensine in man. Psychopharmacologia (1975) 1.12
Alterations of GABA-mediated synaptic transmission in human epilepsy. Adv Neurol (1986) 1.08
Clincial pharmacokinetics in neonates. Clin Pharmacokinet (1976) 1.07
Prevalence of nightmares and their relationship to psychopathology and daytime functioning in insomnia subjects. Sleep (1997) 1.06
[Acute diltiazem poisoning: kinetic and hemodynamics study]. J Toxicol Clin Exp (1991) 1.03
Monosodium glutamate and the Chinese restaurant syndrome. Nature (1970) 1.02
Simple sensitive and specific gas chromatographic method for the quantification of diltiazem human body fluids. J Chromatogr (1977) 1.01
Quinolinic-phosphoribosyl transferase activity is decreased in epileptic human brain tissue. Epilepsia (1988) 1.01
Effect of amantadine on drug-induced parkisonism: relationship between plasma levels and effect. Br J Clin Pharmacol (1976) 1.01
Rapid and sensitive method for determination of haloperidol in human samples using nitrogen-phosphorus selective detection. J Chromatogr (1978) 0.99
Studies on plasma protein binding of carbamazepine. Pharmacol Res Commun (1974) 0.97
Biochemical aspects of Huntington's chorea. J Neurol Neurosurg Psychiatry (1977) 0.97
Bioavailability of two carbamazepine preparations during chronic administration to epileptic patients. Epilepsia (1975) 0.95
Further observations on carbamazepine plasma levels in epileptic patients. Relationships with therapeutic and side effects. Neurology (1976) 0.95
EEG profile of intravenous zolpidem in healthy volunteers. Psychopharmacology (Berl) (1994) 0.95
Blood concentrations and pharmacodynamic effects of betaxolol (SL 75212) a new beta-adrenoceptor antagonist after oral and intravenous administration. Br J Clin Pharmacol (1980) 0.94
Practical experience and issues in designing and performing population pharmacokinetic/pharmacodynamic studies. Eur J Clin Pharmacol (1996) 0.93
Effects of mizolastine and clemastine on actual driving and psychomotor performance in healthy volunteers. Eur J Clin Pharmacol (1994) 0.93
Population pharmacokinetic analysis and optimization of the experimental design for mizolastine solution in children. J Pharmacokinet Pharmacodyn (2001) 0.93
The pharmacokinetics of idraparinux, a long-acting indirect factor Xa inhibitor: population pharmacokinetic analysis from Phase III clinical trials. J Thromb Haemost (2009) 0.93
Monoamine acid metabolites and cerebrospinal fluid dynamics in normal pressure hydrocephalus: preliminary results. J Neurol Neurosurg Psychiatry (1975) 0.93
Lack of interaction between a new antihistamine, mizolastine, and lorazepam on psychomotor performance and memory in healthy volunteers. Br J Clin Pharmacol (1995) 0.91
Comparative pharmacokinetic profile of two imidazopyridine drugs: zolpidem and alpidem. Drug Metab Rev (1992) 0.91
Clinical pharmacokinetics of antiepileptic drugs in adults. Pharmacol Ther (1980) 0.91
Evaluation of memory function in a population of epileptic patients and matched controls. Acta Neurol Scand Suppl (1980) 0.91
A gas chromatographic method for the determination of amantadine in human plasma. J Chromatogr (1972) 0.91
The safety and efficacy of zolpidem in insomniac patients: a long-term open study in general practice. J Int Med Res (1992) 0.90
Carbamazepine: absorption, distribution, and excretion. Adv Neurol (1975) 0.90
A review of the pharmacokinetics, tolerability and pharmacodynamics of amisulpride in healthy volunteers. Hum Psychopharmacol (2002) 0.90
Assessment of the anticholinergic effect of the new antihistamine mizolastine in healthy subjects. Br J Clin Pharmacol (1992) 0.90
Pharmacodynamics and pharmacokinetics of mizolastine (SL 85.0324), a new nonsedative H1 antihistamine. Ann Allergy (1992) 0.89
Determination of progabide and its main acid metabolite in biological fluids using high-performance liquid chromatography and electrochemical detection. Application to the measurement of blood/plasma partition ratio. J Chromatogr (1984) 0.89
Homovanillic acid and 5-hydroxyindole-acetic acid in the csf of patients after a severe head injury. II. Ventricular csf concentrations in acute brain post-traumatic syndromes. Eur Neurol (1975) 0.89
Infants born to hypertensive mothers treated by acebutolol. Pharmacological studies in the perinatal period. Dev Pharmacol Ther (1982) 0.88
gamma-Aminobutyric acid (GABA) receptor stimulation. I. Neuropharmacological profiles of progabide (SL 76002) and SL 75102, with emphasis on their anticonvulsant spectra. J Pharmacol Exp Ther (1982) 0.88
Double-blind crossover trial of progabide versus placebo in severe epilepsies. Epilepsia (1983) 0.88
Absolute bioavailability and electroencephalographic effects of conventional and extended-release formulations of venlafaxine in healthy subjects. J Clin Pharmacol (1998) 0.88
A GLC method for estimation of chlorophenoxyisobutyric acid in plasma. Pharmacokinetics of a single oral dose of clofibrate in man. Eur J Clin Pharmacol (1975) 0.87
Long-term monitoring of tricyclic antidepressant plasma concentrations. Br J Psychiatry (1980) 0.87
A comparison between propranolol, practolol and betaxolol (SL75212) on the circulatory and metabolic responses to insulin-induced hypoglycaemia. Eur J Clin Pharmacol (1981) 0.87
Antipyrine metabolite kinetics in healthy human volunteers during multiple dosing of phenytoin and carbamazepine. Br J Clin Pharmacol (1985) 0.87
Initiation of and adherence to treatment for mental disorders: examination of patient advocate group members in 11 countries. Med Care (2000) 0.86
Beta-blockade and blood-levels after low-dose oral propranolol: The hepatic "first-pass" threshold revisited. Lancet (1978) 0.86
The pharmacokinetic and pharmacodynamic effects of SL65.1498, a GABA-A alpha2,3 selective agonist, in comparison with lorazepam in healthy volunteers. J Psychopharmacol (2008) 0.86
Plasma protein binding of zolpidem in liver and renal insufficiency. Int J Clin Pharmacol Ther Toxicol (1988) 0.86
Psychomotor, Cognitive, extrapyramidal, and affective functions of healthy volunteers during treatment with an atypical (amisulpride) and a classic (haloperidol) antipsychotic. J Clin Psychopharmacol (1999) 0.86
Lymphopenia induced by acute bacterial infections in the elderly: a sign of age-related immune dysfunction of major prognostic significance. Gerontology (1985) 0.85
The potential use of GABA agonists in psychiatric disorders: evidence from studies with progabide in animal models and clinical trials. Pharmacol Biochem Behav (1983) 0.85
Pharmacokinetics of propranolol in normal healthy volunteers. J Pharmacokinet Biopharm (1977) 0.85
The gabaergic hypothesis of depression. Prog Neuropsychopharmacol Biol Psychiatry (1989) 0.85
Diurnal variations in steady-state plasma concentrations of valproic acid in epileptic patients. Clin Pharmacokinet (1983) 0.85
Beta-adrenoceptor blocking effects and pharmacokinetics of betaxolol (SL 75212) in man. Br J Clin Pharmacol (1980) 0.84
High-performance liquid chromatographic determination of zolpidem, a new sleep inducer, in biological fluids with fluorimetric detection. J Chromatogr (1986) 0.84
Carbamazepine: biotransformation. Adv Neurol (1975) 0.84
The effect of injections of fluorocitrate into the brains of rats. Biochem Pharmacol (1968) 0.84
High-performance liquid and gas chromatographic methods for the determination of cicloprolol. J Chromatogr (1990) 0.84
Pharmacokinetic analysis of mizolastine in healthy young volunteers after single oral and intravenous doses: noncompartmental approach and compartmental modeling. J Pharmacokinet Biopharm (1997) 0.84
Carbamazepine/valproic acid interaction in man and rhesus monkey. Epilepsia (1984) 0.83